Dual-specificity phosphatase 5 attenuates autoimmune arthritis in mice via reciprocal regulation of the Th17/Treg cell balance and inhibition of osteoclastogenesis

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3083-3095

  Moon, Su Jin ^a   Lim, Mi Ae ^a   Park, Jin Sil ^a   Byun, Jae Kyeong ^a   Kim, Sung Min ^a   Park, Mi Kyung ^a   Kim, Eun Kyung ^a   Moon, Young Mee ^a   Min, Jun Ki ^a   Ahn, Sung Min ^b   Park, Sung Hwan ^a   Cho, Mi La ^a  

^a The Catholic University of Korea   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BETA3 INTEGRIN; CATHEPSIN K; CD4 ANTIGEN; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; COLONY STIMULATING FACTOR 1; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 5; GELATINASE B; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOCLAST DIFFERENTIATION FACTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIBODY; DUSP5 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; STAT5 PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HISTOLOGY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SPLEEN; TH17 CELL; UPREGULATION; WESTERN BLOTTING; ANIMAL; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CELL COMMUNICATION; CELL PROLIFERATION; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; OSTEOCLAST; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CELL COMMUNICATION; CELL PROLIFERATION; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DUAL-SPECIFICITY PHOSPHATASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; IN VITRO TECHNIQUES; INFLAMMATION; MALE; MICE; MICE, INBRED DBA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOCLASTS; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84925581289     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38787     Document Type: Article

References (35)

1. Takayanagi H,. New developments in osteoimmunology. Nat Rev Rheumatol 2012; 8: 684-9.
2. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR,. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943-51.
3. Takayanagi H,. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5: 667-76.
4. Kageyama Y, Koide Y, Yoshida A, Uchijima M, Arai T, Miyamoto S, et al., Reduced susceptibility to collagen-induced arthritis in mice deficient in IFN-γ receptor. J Immunol 1998; 161: 1542-8.
5. Lubberts E, Koenders MI, van den Berg WB,. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7: 29-37.
6. Wei L, Laurence A, O'Shea JJ,. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol 2008; 19: 394-400.
7. Takayanagi H,. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292-304.
8. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27.
9. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al., Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277-85.
10. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140: 360-7.
11. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al., Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2501-12.
12. Keyse SM,. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 27: 253-61.
13. Wang Z, Reinach PS, Zhang F, Vellonen KS, Urtti A, Turner H, et al., DUSP5 and DUSP6 modulate corneal epithelial cell proliferation. Mol Vis 2010; 16: 1696-704.
14. Singh K, Deshpande P, Pryshchep S, Colmegna I, Liarski V, Weyand CM, et al., ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. J Immunol 2009; 183: 8258-67.
15. Lewis DL, Wolff JA,. Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol 2005; 392: 336-50.
16. Bettan M, Emmanuel F, Darteil R, Caillaud JM, Soubrier F, Delaere P, et al., High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther 2000; 2: 204-10.
17. Brand DD, Latham KA, Rosloniec EF,. Collagen-induced arthritis. Nat Protoc 2007; 2: 1269-75.
18. Rosloniec EF, Cremer M, Kang A, Myers LK,. Collagen-induced arthritis. Curr Protoc Immunol 2001;Chapter 15:Unit 15.5 1-25.
19. Choy E,. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 5: v3-11.
20. Marrelli A, Cipriani P, Liakouli V, Carubbi F, Perricone C, Perricone R, et al., Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev 2011; 10: 595-8.
21. Ferrara N, Gerber HP, LeCouter J,. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
22. Fraser A, Fearon U, Reece R, Emery P, Veale DJ,. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001; 44: 2024-8.
23. Wei L, Laurence A, Elias KM, O'Shea JJ,. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007; 282: 34605-10.
24. H-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007; 8: 958-66.
25. H17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453: 65-71.
26. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS,. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999; 291: 124-30.
27. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G,. Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2745-56.
28. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, DeLora P, et al., Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60: 335-44.
29. Damjanov N, Kauffman RS, Spencer-Green GT,. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60: 1232-41.
30. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, et al., A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011; 38: 846-54.
31. Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, et al., Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 2005; 48: 5966-79.
32. Cheung PC, Campbell DG, Nebreda AR, Cohen P,. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J 2003; 22: 5793-805.
33. Mandl M, Slack DN, Keyse SM,. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol 2005; 25: 1830-45.
34. Kozanidou VI, Theocharis AD, Georgiadis A, Voulgari PV, Drosos AA, Karamanos NK,. Signal transduction by IL-2 and its receptors as target in treatment of rheumatoid arthritis. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 41-50.
35. c-family cytokine target genes: identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J Biol Chem 2003; 278: 5205-13.